Skip to main content
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. logo

DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 688192 ISIN · CNE1000055W8 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688192

About DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.

https://www.dizalpharma.com/

Dizal (Jiangsu) Pharmaceutical Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for cancer and autoimmune diseases. Originating from AstraZeneca's Innovation Center China, the company leverages a proprietary translational medicine platform and structure-based drug design capabilities to address unmet medical needs globally. Its portfolio features several clinical-stage assets, notably sunvozertinib, a selective EGFR tyrosine kinase inhibitor for non-small cell lung cancer with Exon20 insertion mutations, and golidocitinib, a JAK1-selective inhibitor for peripheral T-cell lymphoma. Dizal focuses on developing first-in-class and best-in-class medicines through a science-driven approach, maintaining a robust pipeline of small molecule candidates aimed at precision oncology and immunology.

Recent filings

Filing Released Lang Actions
迪哲医药：自愿披露关于血液瘤产品高瑞哲和比瑞替尼（birelentinib）研究成果入选2026年欧洲血液学协会（EHA）年会的公告
Regulatory Filings Classification · 78% confidence The document is a voluntary corporate announcement by Dize (Jiangsu) Pharmaceuticals disclosing that its blood tumor drug research results have been selected for presentation at the 2026 EHA annual meeting. It contains no financial statements or regulatory certifications, dividends, share transactions, or management changes. It is a general regulatory disclosure under the Shanghai Stock Exchange rules and does not fit any specific financial report category, so it should be classified as Regulatory Filings (RNS).
2026-05-13 Chinese
迪哲医药：关于变更持续督导保荐代表人的公告
Regulatory Filings Classification · 82% confidence The document is an official announcement from Dize (Jiangsu) Pharmaceutical Co. regarding the replacement of continuous supervision sponsor representatives appointed by an underwriting institution. It contains no financial statements or investment terms but rather a regulatory notice of personnel changes related to sponsorship supervision. This does not fit any specific financial report or transaction category and is best classified under the general regulatory announcements fallback, RNS.
2026-05-11 Chinese
迪哲医药：关于参加“对话成长”2025年度暨2026年一季度集体业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's participation in an investor performance explanation meeting for the 2025 annual and 2026 first quarter results. It references that the company has already published the 2025 annual report and the 2026 Q1 report. The document details the meeting time, format, platform, and participants, but does not contain actual financial data or detailed financial statements. It is essentially an announcement of an investor presentation event rather than the presentation or report itself. The document length is short (1249 characters), and it serves to inform investors about the upcoming event and how to participate. Therefore, it fits best as an Investor Presentation (IP) announcement rather than a full report or a report publication announcement (RPA).
2026-05-06 Chinese
迪哲医药：2025年年度股东会会议资料
AGM Information Classification · 92% confidence The document is a full set of materials for the 2025 Annual General Meeting of Dizal (Jiangsu) Pharmaceutical Co., Ltd. It includes the meeting notice, agenda, explanatory proposals, board reports, financial statements proposals, and governance proposals specifically for the shareholders’ meeting. This fits the definition of AGM Information (materials presented at the AGM), not an Annual Report or just an announcement. Therefore, it should be classified as AGM Information (AGM-R).
2026-04-14 Chinese
迪哲医药：2022年限制性股票激励计划首次授予的第一类激励对象第三个归属期第二次归属结果暨股票上市公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company regarding the listing of shares related to a restricted stock incentive plan. It details the stock grant, the decision-making process, the number of shares, the listing date, and the impact on share capital and earnings per share. It references multiple board and shareholder meetings approving the stock incentive plan and the registration of shares. The document is a formal announcement of the stock listing event and related share capital changes, not a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it fits best into the category of Share Issue/Capital Change (SHA), which covers announcements about new share issues and capital changes.
2026-04-09 Chinese
迪哲医药：2025年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2025 年年度报告摘要" which translates to "2025 Annual Report Summary" for Dizal Pharma (迪哲医药). It contains detailed financial data for the year 2025, including revenue, net profit, assets, and quarterly breakdowns. It also includes extensive management discussion and analysis of business operations, product pipeline, industry context, and future outlook. The document references the full annual report and states that the summary is derived from the full annual report. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K).
2026-03-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.